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Acute phosphate nephropathy (APhN) following oral sodium phosphate solution
(OSP) ingestion as a bowel purgative has been frequently reported. It was recently
suggested that APhN could progress to chronic kidney disease (CKD) and a history
of APhN might be considered as one of the causes of CKD. However, there are few
reports proving APhN as a cause of CKD. Here, we report a case of APhN that
progressed to CKD, as proven by renal biopsy.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Colonoscopy is a widespread diagnostic tool for the evalua-
tion of colonic diseases. Bowel preparation is an important factor
in obtaining an accurate diagnosis. Patients use a purgative
the day before the procedure to improve the accuracy of the
diagnosis. Oral sodium phosphate (OSP) and polyethylene glycol
(PEG) solutions are commonly used for bowel preparation
because of their ease of use and their safety proﬁle [1].
OSP has an advantage over PEG in terms of a lower ﬂuid
volume to be ingested (two bottles of 45 mL each). Initially, the
adverse effects of this agent were unremarkable, especially in
patients with normal kidney function. However, because of
cases of OSP-induced acute renal failure, the safety of OSP has
been questioned [2]. Furthermore, it was noted that acute renal
failure can progress to chronic kidney disease (CKD) [3]. Here,
we report a case of CKD caused by acute phosphate nephro-
pathy (APhN) following use of OSP as a bowel purgative.rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
al Medicine, Nephrology
pital, 7-206, 3-ga,
orea.Case report
A 51-year-old woman was admitted to Inha University
Hospital for evaluation of renal failure that was recently found
at a local clinic.
She had been diagnosed with essential hypertension
3 years previously, which was managed with hydrochlor-
othiazide 12.5 mg and candesartan 16 mg once a day. Her
other previous medical history was unremarkable. She took
ibuprofen 400 mg on the initial day of menstruation on a
monthly basis for 30 years to relieve abdominal pain. Seven
months previously, she underwent a health screening exam-
ination. Bowel preparation involved ingestion of OSP (Phos-
pho Soda, Fleet, USA). After 8 hours of NPO, she visited the
health promotion center at 09:00 hours. Blood and urine were
sampled for laboratory examination. Then, esophagogastro-
duodenoscopy (EGD) and colonoscopy were performed under
anesthesia using intravenous midazolam 5 mg. Serum blood
urea nitrogen (BUN; 8.8 mg/dL), creatinine (0.86 mg/dL), cal-
cium (9.0 mg/dL), phosphate (4.7 mg/dL), and albumin (4.3 g/
dL)) were all normal at that time. EGD and colonoscopy ﬁndings
were normal. However, the patient suffered from persistent
nausea and anorexia after the screening examination.ublished by Elsevier. This is an open access article under the CC BY-NC-
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pressure was 130/70 mmHg, pulse rate was 72/minute, and
body temperature was 37 1C.
Blood tests yielded the following results: hemoglobin 8.3 g/dL,
platelets 350,000/mL, white blood cells 8170/mL, BUN
42.5 mg/dL, creatinine 2.95 mg/dL, calcium 8.5 mg/dL, phos-
phate 3.7 mg/dL, total protein 7.9 g/dL, albumin 4.0 g/dL,
glucose 102 mg/dL, sodium 140 mEq/L, potassium 4.6 mEq/L,
chloride 103 mEq/L, and total CO2 21.4 mEq/L. C3 was
134 mg/dL, C4 was 34 mg/dL, and antinuclear antibody,
anti-neutrophil cytoplasm antibody, cryoglobulin, RA factor,
anti-ds DNA antibody, and anti-GBM antibody tests were all
negative. Serum iron was 40 mg/dL, total iron-binding capa-
city was 303 mg/dL, ferritin was 28.7 mg/mL, and stool occult
blood was negative according to EGD. Serum and urine
electrophoresis analyses were normal. Urine speciﬁc gravity
was 1.009 and protein and blood were negative. The 24-hour
urine volume was 3700 mL, with protein of 595 mg and
creatinine of 1.0 g.
A bone marrow biopsy showed no evidence of multiple
myeloma or other diseases. Abdominal ultrasonography showed
an increased renal cortical echo-texture. However, renal contour
and size were normal (right 11.9 cm, left 11.3 cm, long axis;
Fig. 1) and there was no evidence of a renal stone or
hydronephrosis.Figure 1. Abdominal ultrasonography showed increased renal cor-
tical echo-texture, but the renal contour and size were normal
(right, 11.9 cm; left, 11.3 cm, long axis).
Figure 2. The kidney biopsy showed tubular atrophies or dilation
(Masson’s trichrome stain, 100 (a) and scattered calciﬁcations
within the tubules (hematoxylin and eosin stain, 100 (b).The patient was hydrated with 1–2 L of normal saline for
10 day. However, her serum creatinine level remained ele-
vated (2.74 mg/dL). To ﬁnd the cause of renal failure, a kidney
biopsy was performed on Day 10. Pathologic analysis of the
kidney biopsy showed tubular atrophy or dilation (Fig. 2A).
Multifocal scattered calciﬁcations were present within the
tubules, mainly in the distal tubules (Fig. 2B). The tubular
epithelial cells were simpliﬁed and showed degenerative and
regenerative changes. The interstitium showed a moderate
degree of ﬁbrosis and inﬂammatory cell inﬁltration, mainly of
lymphocytes and some neutrophils (Fig. 3). The tubular
calciﬁcations did not polarize and were positive to von Kossa
stain (Fig. 3), which conﬁrmed their composition as calcium
phosphate. The glomeruli appeared mildly enlarged and there
were no capillary wall changes. Immunohistochemistry was
negative for immunoglobulins and for complement factors.
After kidney biopsy, a further examination was performed to
rule out other causes of nephrocalcinosis. Serum intact parathyr-
oid hormone (iPTH) decreased from an initial level of 186 pg/mL
to 54.6 pg/mL after 2 months. Results for 24-hour urinary
analytes were as follows: sodium, 98mEq/day (normal range
40–220 mEq/day); uric acid, 425mg/day (250–750mg/day);
Figure 3. A positive histochemical reaction with von Kossa stain
conﬁrms that the tubular concretions are composed of calcium
phosphate (100 ).
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(16.20–53.30 mg/day); calcium, 35.0 mg/day (70.0–180.0 mg/
day); and creatinine, 0.9 g/day (1.0–2.0 g/day).
Supportive treatment was given and the patient’s kidney
function remained unchanged 3 months later, with a creati-
nine level of 2.21 mg/dL.Discussion
This case shows that exposure to OSP as a bowel purgative
is associated with the development of APhN in patients with
risk factors and can progress to CKD. Furthermore, in CKD
patients with unknown cause, clinicians should consider that
use of an OSP bowel purgative may be one of the possible
causes of the development of CKD.
OSP preparations are osmotic purgatives that obligate water
excretion into the intestinal lumen to maintain its isotonicity
with plasma [2]. Retention of water in the bowel lumen results
in peristalsis and colonic evacuation. The high osmolarity of
OSP is due to its high sodium and phosphate content [2]. Each
45-mL dose of Phospho Soda contains 5 g of sodium and
17.8 g of phosphate, yielding a solution with osmolarity of
16,622 mOsm/L [2]. Various complications, including hyper-
phosphatemia, hypocalcemia, hypernatremia, hypokalemia,
metabolic acidosis, and acute kidney injury (AKI), have been
reported in association with OSP ingestion [4]. Hyperpho-
sphatemia is considered to be a major cause of OSP-induced
AKI. Therefore, Desmeules et al. used the term APhN for AKI
following OSP use as a bowel purgative [5]. The incidence has
been reported as 1.29–5.0% [6,7].
Calcium phosphate deposition in renal tubules and inter-
stitium appears to be a mechanism underlying APhN and has
been demonstrated histopathologically using von Kossa
stain [7]. Nephrocalcinosis occurs when calcium precipitates
in conjunction with either oxalate or phosphate [2]. The
phosphates in calcium phosphate deposits are detected in
parafﬁn sections using von Kossa stain [2], which involves a
precipitation reaction in which silver ions react with phosphate
to yield a black product. This stain does not detect purecalcium oxalate [2]. In the case of hyperparathyroidism,
calcium salts are typically found along medullary tubular
basement membranes, as concretions within tubules, and in
the interstitium [4]. By contrast, the calcium phosphate depos-
its seen in APhN are found primarily in the tubular lumen and
the cytoplasm of tubular epithelial cells, with rare interstitial
deposits as well [8]. Hypercalciuria and hyperoxaluria are also
risk factors for nephrocalcinosis [2]. In our case, the elevated
serum iPTH level seemed to be due to CKD, and biopsies in
such cases show calcium phosphate deposits, primarily in the
tubular lumen. Our case did not show hypercalcuria, hyperox-
aluria or a history of herb ingestion. Among patients with CKD
of unknown cause, it has been reported that Chinese herb
nephropathy may be an etiologic agent, in which progressive
tubulointerstitial nephritis and development of end-stage renal
disease within 1–2 years are characteristics [9,10]. Our patient
did not have a history of herb ingestion.
Following intake of a large amount of phosphate, proximal
tubular phosphate reabsorption is decreased, leading to a
rapid increase in delivery to the distal tubule [11]. Diarrhea-
induced hypovolemia leads to avid salt and water reabsorp-
tion in both the proximal tubule and the descending limb of
Henle’s loop, which is relatively impermeable to calcium and
phosphate [12]. The net effect is a decrease in phosphate
reabsorption in the proximal tubule, leading to a marked
increase in calcium–phosphorus products within the lumen of
the distal tubule [8]. Hypovolemia-associated tubular injury
may also precondition the distal tubular epithelium, leading
to surface expression of hyaluronan and osteopontin, which in
turn creates a suitable environment for adherence of calcium
phosphate crystals [12]. A direct toxic effect of hyperpho-
sphatemia on renal tubules is proposed as one of the mechan-
isms of renal failure after OSP use. In a rat model of APhN
involving intravenous administration of phosphorus, Zarger
et al. observed vacuolization of tubular cells without calcium
phosphate deposition in renal biopsies [16].
Old age, female gender, liver disease, renal disease,
decreased bowel motility, hypertension, diabetes, and medi-
cations contributing to renal hypoperfusion, such as diuretics,
angiotensin-converting enzyme inhibitors and angiotensin
(AT)–II receptor blockers, could predispose to this disorder
[11]. In our case, the patient had risk factors of female gender,
hypertension, and AT-II receptor blocker use.
The development of CKD in APhN following the use of OSP
has been reported [12]. The pathophysiology has not been
elucidated yet, but it appears to be associated with activation
of the innate immune system in mediating the pro-inﬂam-
matory effects of tissue crystal deposition [2]. Pattern recog-
nition receptors, such as the Toll-like receptor (TLR), mediate
monosodium urate monohydrate-dependent nitric oxide and
IL-1b release from chondrocytes and macrophages, respec-
tively [2]. Given the ability of speciﬁc TLRs to recognize
calcium crystals and the expression of a variety of TLRs in
adult kidney, it is possible that intraluminal calcium phos-
phate crystal formation after OSP is recognized by speciﬁc
epithelial TLRs, with subsequent activation of the innate
immune response [13]. Persistence of these crystals could
result in chronic inﬂammation with extracellular matrix
deposition and interstitial ﬁbrosis [14].
We speculate that iron deﬁciency anemia in our case was
caused by a decreased iron intake due to persistent anorexia.
There are only a few reports in terms of CKD after APhN
following OSP ingestion as a bowel purgative so far in Korea.
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purgative in a 66-year-old female [15]. We report a case of
APhN that progressed to CKD, as proven by renal biopsy, in a
female patient of normal renal function prior to colonoscopy.Conﬂict of interest
None declared.
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